Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Low body weight and type of protease inhibitor predict discontinuation and treatment-limiting adverse drug reactions among HIV-infected patients starting a protease inhibitor regimen: consistent results from a randomized trial and an observational cohort.

Research output: Contribution to journalJournal articleResearch

  1. Cardiac chamber volumes and left ventricular mass in people living with HIV and matched uninfected controls

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. 2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Risk factors during pregnancy and birth-related complications in HIV-positive versus HIV-negative women in Denmark, 2002-2014

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Poor concordance between liver stiffness and non-invasive fibrosis scores in HIV infection without viral hepatitis

    Research output: Contribution to journalShort surveyResearchpeer-review

  2. Associations of the gut microbiome and clinical factors with acute GVHD in allogeneic HSCT recipients

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Remdesivir for the Treatment of Covid-19 - Final Report

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
OBJECTIVES: To assess predictors for discontinuation and treatment-limiting adverse drug reactions (TLADR) among patients starting their first protease inhibitor (PI). METHODS: Data on patients starting a PI regimen (indinavir, ritonavir, ritonavir/saquinavir and saquinavir hard gel) in a randomized trial (RAS, n = 318) and an observational cohort (OBC, n = 505) were used to document reasons for discontinuation and TLADR. Risk factors for discontinuation of the initial PI/developing TLADR were assessed in Cox models. RESULTS: A total of 43 (RAS) and 48% (OBC) discontinued the initial PI therapy within less than 2 years. In both populations TLADR were the most common reason for discontinuation. The incidence of TLADR in RAS was: 8.5 (indinavir), 66.0 (ritonavir), 15.6 (saquinavir hard gel) per 100 person-years of follow-up (P < 0.001). Body weight and type of PI initiated were independent risk factors for treatment discontinuation and TLADR in both groups. In OBC, the risk of developing TLADR increased by 12% per 5 kg lower body weight when starting the PI regimen [the relative hazard (RH) was 1.12 (95% confidence interval: 1.05-1.19) per 5 kg lighter], and starting ritonavir was associated with a three- to sixfold higher risk of TLADR relative to other PI regimens. Very similar results were documented in RAS [RH for body weight was 1.18 (1.07-1.29)]. CONCLUSIONS: Nearly half of the patients stopped treatment with the initial PI, most commonly as a result of adverse drug reactions. Low body weight and initiation of ritonavir relative to other PIs were associated with an increased risk of TLADRs. Very consistent results were found in a randomized trial and an observational cohort.
Translated title of the contributionLow body weight and type of protease inhibitor predict discontinuation and treatment-limiting adverse drug reactions among HIV-infected patients starting a protease inhibitor regimen: consistent results from a randomized trial and an observational cohort.
Original languageEnglish
JournalHIV Medicine
Volume2
Issue number1
Pages (from-to)43-51
Number of pages9
ISSN1464-2662
Publication statusPublished - 2001

ID: 32509126